A clinical randomized controlled trial of a treatment plan for locally advanced inoperable NSCLC guided by FMISO&FDG-PET/CT

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027355

Enrollment

Unknown

Registered

2019-11-10

Start date

2020-09-01

Completion date

Unknown

Last updated

2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Experimental group:Cumulative radiotherapy 66 Gy, 2Gy×19f, once/day.

Control group:Cumulative radiotherapy 60 Gy, 2Gy×16f, once/day.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Pathological examination confirmed non-small cell lung cancer (NSCLC); 2. Locally advanced NSCLC that is surgically inoperable or the patient refuses surgery; 3. The lesion area indicated by PET is SUVmax >= 2.5; 4. Blood routine, liver, kidney function and heart function are basically normal.

Exclusion criteria

Exclusion criteria: 1. KPS <= 70 points; 2. Pulmonary function is severely ventilatory dysfunction; 3. Marrow suppression above 3; 4. Moderate to severe cardiac insufficiency.

Design outcomes

Primary

Measure	Time frame
Tumor SUVmax;hypoxia area;radiotherapy dose;	—

Secondary

Measure	Time frame
Tumor volume;Tumor retraction rate;	—

Countries

China

Contacts

Public ContactYingqiu Song

Liaoning Cancer Hospital

1018501023@qq.com+86 18900917411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026